Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections and associated practice patterns in allogeneic hematopoietic cell transplant recipients. It is expected that participating centers will be in the United Kingdom, France, Spain, Germany, and Italy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with non-relapse related mortality 3 and 6 months after first AdV Virema in paediatric allo-HCT recipients | To assess non-relapse related mortality 3 to 6 months after first adenovirus viremia. | 3 and 6 months after first adenovirus viremia |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants who were hospitalized To assess the number of hospitalizations | To assess the number of hospitalizations, length of stay, and ICU stay. | 3 to 6 months |
| The rate of adenovirus infection progression |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
compromised of all allo-HCT recipients at participating centers during the pre-specified study period
Not provided
| ID | Term |
|---|---|
| D000258 | Adenovirus Infections, Human |
| ID | Term |
|---|---|
| D000257 | Adenoviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the rate of progression to disseminated adenovirus disease within the first year following allo-HCT
| 3 to 6 months |